Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Proc Natl Acad Sci U S A ; 109(2): 576-81, 2012 Jan 10.
Article in English | MEDLINE | ID: mdl-22203977

ABSTRACT

Diverse mutations in the genes encoding hemoglobin (Hb) have been characterized in human disease. We describe here a mutation in the mouse Hbb-b2 gene, denoted Plt12, that precisely mimics the human hemoglobin Hotel Dieu variant. The mutation results in increased affinity of Hb for oxygen and Plt12 mutant mice exhibited reduced partial pressure of O(2) in the blood, accompanied by erythrocytosis characterized by elevated erythropoietin levels and splenomegaly with excess erythropoiesis. Most homozygous Hbb-b2(Plt12/Plt12) mice succumbed to early lethality associated with emphysema, cardiac abnormalities, and liver degeneration. Survivors displayed a marked thrombocytopenia without significant deficiencies in the numbers of megakaryocytes or megakaryocyte progenitor cells. The lifespan of platelets in the circulation of Hbb-b2(Plt12/Plt12) mice was normal, and splenectomy did not correct the thrombocytopenia, suggesting that increased sequestration was unlikely to be a major contributor. These data, together with the observation that megakaryocytes in Hbb-b2(Plt12/Plt12) mice appeared smaller and deficient in cytoplasm, support a model in which hypoxia causes thrombocytopenia as a consequence of an inability of megakaryocytes, once formed, to properly mature and produce sufficient platelets. The Plt12 mouse is a model of high O(2)-affinity hemoglobinopathy and provides insights into hematopoiesis under conditions of chronic hypoxia.


Subject(s)
Hemoglobins, Abnormal/genetics , Polycythemia/genetics , Thrombocytopenia/genetics , Animals , Blood Cell Count , Blood Gas Analysis , Erythropoiesis/genetics , Erythropoietin/blood , Half-Life , Male , Megakaryocytes/metabolism , Mice , Mice, Inbred BALB C , Mice, Mutant Strains , Mutation/genetics , Oxygen/blood , Polycythemia/pathology , Splenomegaly , Thrombocytopenia/pathology
2.
Blood ; 117(20): 5362-71, 2011 May 19.
Article in English | MEDLINE | ID: mdl-21421839

ABSTRACT

In a recessive ENU mutagenesis screen for embryonic lethality, we identified a mouse pedigree with a missense mutation of SHIP1 (SHIP1(el20)) leading to an amino acid substitution I641T in the inositol-5'-phosphatase domain that represses phosphatidylinositol-3-kinase signaling. Despite detectable expression of functional SHIP1 protein, the phenotype of homozygous SHIP1(el20/el20) mice was more severe than gene-targeted SHIP1-null (SHIP1(-/-)) mice. Compared with age-matched SHIP1(-/-) mice, 5-week-old SHIP1(el20/el20) mice had increased myeloid cells, serum IL-6 levels, marked reductions in lymphoid cells, and died by 7 weeks of age with infiltration of the lungs by activated macrophages. Bone marrow transplantation demonstrated that these defects were hematopoietic-cell-autonomous. We show that the el20 mutation reduces expression in SHIP1(el20/el20) macrophages of both SHIP1 and s-SHIP, an isoform of SHIP1 generated by an internal promoter. In contrast, SHIP1(-/-) macrophages express normal levels of s-SHIP. Compound heterozygous mice (SHIP1(-/el20)) had the same phenotype as SHIP1(-/-) mice, thus providing genetic proof that the more severe phenotype of SHIP1(el20/el20) mice is probably the result of concomitant loss of SHIP1 and s-SHIP. Our results suggest that s-SHIP synergizes with SHIP1 for suppression of macrophage activation, thus providing the first evidence for a role of s-SHIP in adult hematopoiesis.


Subject(s)
Macrophage Activation/genetics , Macrophage Activation/physiology , Phosphoric Monoester Hydrolases/genetics , Phosphoric Monoester Hydrolases/physiology , Amino Acid Substitution , Animals , Base Sequence , Bone Marrow Transplantation , DNA Primers/genetics , Embryonic Stem Cells/cytology , Embryonic Stem Cells/metabolism , Ethylnitrosourea , Female , Genes, Recessive , Hematopoiesis/genetics , Hematopoiesis/physiology , Homozygote , Inositol Polyphosphate 5-Phosphatases , Interleukin-6/biosynthesis , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Mice, Mutant Strains , Mutagenesis , Mutation, Missense , Phenotype , Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases , Phosphoric Monoester Hydrolases/deficiency , Protein Isoforms/deficiency , Protein Isoforms/genetics , Protein Isoforms/physiology , Signal Transduction
3.
Proc Natl Acad Sci U S A ; 107(38): 16625-30, 2010 Sep 21.
Article in English | MEDLINE | ID: mdl-20823251

ABSTRACT

With the notable exception of humans, uric acid is degraded to (S)-allantoin in a biochemical pathway catalyzed by urate oxidase, 5-hydroxyisourate (HIU) hydrolase, and 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase in most vertebrate species. A point mutation in the gene encoding mouse HIU hydrolase, Urah, that perturbed uric acid metabolism within the liver was discovered during a mutagenesis screen in mice. The predicted substitution of cysteine for tyrosine in a conserved helical region of the mutant-encoded HIU hydrolase resulted in undetectable protein expression. Mice homozygous for this mutation developed elevated platelet counts secondary to excess thrombopoietin production and hepatomegaly. The majority of homozygous mutant mice also developed hepatocellular carcinoma, and tumor development was accelerated by exposure to radiation. The development of hepatomegaly and liver tumors in mice lacking Urah suggests that uric acid metabolites may be toxic and that urate oxidase activity without HIU hydrolase function may affect liver growth and transformation. The absence of HIU hydrolase in humans predicts slowed metabolism of HIU after clinical administration of exogenous urate oxidase in conditions of uric acid-related pathology. The data suggest that prolonged urate oxidase therapy should be combined with careful assessment of toxicity associated with extrahepatic production of uric acid metabolites.


Subject(s)
Amidohydrolases/deficiency , Amidohydrolases/genetics , Hepatomegaly/enzymology , Hepatomegaly/genetics , Liver Neoplasms, Experimental/enzymology , Liver Neoplasms, Experimental/genetics , Point Mutation , Amidohydrolases/chemistry , Amidohydrolases/metabolism , Amino Acid Sequence , Animals , Female , Genes, Tumor Suppressor , Hepatocytes/enzymology , Hepatomegaly/etiology , Liver Neoplasms, Experimental/etiology , Male , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Mutant Strains , Mice, Transgenic , Models, Molecular , Molecular Sequence Data , Mutagenesis , Mutant Proteins/chemistry , Mutant Proteins/genetics , Mutant Proteins/metabolism , Phenotype , RNA, Messenger/genetics , RNA, Messenger/metabolism , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Sequence Homology, Amino Acid , Thrombocytosis/enzymology , Thrombocytosis/genetics , Thrombopoietin/biosynthesis , Urate Oxidase/metabolism , Uric Acid/metabolism , Uric Acid/toxicity
4.
PLoS Genet ; 4(9): e1000192, 2008 Sep 19.
Article in English | MEDLINE | ID: mdl-18802465

ABSTRACT

Harlequin Ichthyosis (HI) is a severe and often lethal hyperkeratotic skin disease caused by mutations in the ABCA12 transport protein. In keratinocytes, ABCA12 is thought to regulate the transfer of lipids into small intracellular trafficking vesicles known as lamellar bodies. However, the nature and scope of this regulation remains unclear. As part of an original recessive mouse ENU mutagenesis screen, we have identified and characterised an animal model of HI and showed that it displays many of the hallmarks of the disease including hyperkeratosis, loss of barrier function, and defects in lipid homeostasis. We have used this model to follow disease progression in utero and present evidence that loss of Abca12 function leads to premature differentiation of basal keratinocytes. A comprehensive analysis of lipid levels in mutant epidermis demonstrated profound defects in lipid homeostasis, illustrating for the first time the extent to which Abca12 plays a pivotal role in maintaining lipid balance in the skin. To further investigate the scope of Abca12's activity, we have utilised cells from the mutant mouse to ascribe direct transport functions to the protein and, in doing so, we demonstrate activities independent of its role in lamellar body function. These cells have severely impaired lipid efflux leading to intracellular accumulation of neutral lipids. Furthermore, we identify Abca12 as a mediator of Abca1-regulated cellular cholesterol efflux, a finding that may have significant implications for other diseases of lipid metabolism and homeostasis, including atherosclerosis.


Subject(s)
ATP-Binding Cassette Transporters/metabolism , Homeostasis , Ichthyosis, Lamellar/metabolism , Lipid Metabolism , ATP-Binding Cassette Transporters/genetics , Animals , Biological Transport , Cell Differentiation , Disease Models, Animal , Epidermis/metabolism , Epidermis/physiopathology , Ethylnitrosourea/pharmacology , Female , Humans , Ichthyosis, Lamellar/embryology , Ichthyosis, Lamellar/genetics , Ichthyosis, Lamellar/physiopathology , Keratinocytes/metabolism , Male , Mice , Mice, Inbred C57BL , Mutagenesis , Skin/metabolism , Skin/physiopathology
5.
Blood ; 112(8): 3148-53, 2008 Oct 15.
Article in English | MEDLINE | ID: mdl-18684867

ABSTRACT

In an N-nitroso-N-ethylurea (ENU) mutagenesis screen using Mpl(-/-) mice, we isolated a semidominant suppressor of thrombocytopenia, termed Plt6. The gene mutated in Plt6 mice encodes the transcriptional coregulator p300, and the mutation, a tyrosine to asparagine substitution at amino acid 630 (Y630N), disrupts the interaction between p300 and c-Myb. Mpl(-/-) p300(Plt6/+) mice displayed elevated platelet counts relative to Mpl(-/-) p300(+/+) controls, whereas mice homozygous for the Plt6 mutation produced supraphysiological levels of circulating platelets. On a wild-type genetic background, mice homozygous for the p300(Plt6) mutation, or recipients of Mpl(+/+) p300(Plt6/Plt6) bone marrow, also exhibited thrombocytosis as well as deficiencies in B-lymphoid cells. Increased platelet numbers in Plt6 mutant mice were accompanied by significant increases in megakaryocyte progenitor cells within the bone marrow and spleen with concomitantly elevated numbers of megakaryocytes. The expansion of megakaryocytopoiesis and suppression of Mpl(-/-) thrombocytopenia in Plt6 mutants is highly reminiscent of that observed in mice with mutations affecting the p300 partner protein c-Myb, suggesting an indispensable repressive role for the c-Myb/p300 transcriptional regulatory complex in megakaryocyte development, the inhibition of which allows substantial thrombopoietin (TPO)-independent platelet production.


Subject(s)
Blood Platelets/metabolism , E1A-Associated p300 Protein/physiology , Mutation , Point Mutation , Proto-Oncogene Proteins c-myb/physiology , Receptors, Thrombopoietin/genetics , Thrombocytopenia/genetics , Animals , Base Sequence , E1A-Associated p300 Protein/genetics , Homozygote , Megakaryocytes/cytology , Mice , Mice, Inbred C57BL , Molecular Sequence Data , Proto-Oncogene Proteins c-myb/metabolism , Thrombopoietin/metabolism
6.
PLoS Biol ; 6(4): e93, 2008 Apr 15.
Article in English | MEDLINE | ID: mdl-18416604

ABSTRACT

Polycomb group proteins are transcriptional repressors that play a central role in the establishment and maintenance of gene expression patterns during development. Using mice with an N-ethyl-N-nitrosourea (ENU)-induced mutation in Suppressor of Zeste 12 (Suz12), a core component of Polycomb Repressive Complex 2 (PRC2), we show here that loss of Suz12 function enhances hematopoietic stem cell (HSC) activity. In addition to these effects on a wild-type genetic background, mutations in Suz12 are sufficient to ameliorate the stem cell defect and thrombocytopenia present in mice that lack the thrombopoietin receptor (c-Mpl). To investigate the molecular targets of the PRC2 complex in the HSC compartment, we examined changes in global patterns of gene expression in cells deficient in Suz12. We identified a distinct set of genes that are regulated by Suz12 in hematopoietic cells, including eight genes that appear to be highly responsive to PRC2 function within this compartment. These data suggest that PRC2 is required to maintain a specific gene expression pattern in hematopoiesis that is indispensable to normal stem cell function.


Subject(s)
Hematopoietic Stem Cells/metabolism , Repressor Proteins/metabolism , Alleles , Animals , Female , Male , Mice , Mice, Transgenic , Mutation , Phenotype , Polycomb Repressive Complex 2 , Polycomb-Group Proteins , RNA, Messenger/metabolism , Repressor Proteins/genetics
7.
J Immunol ; 179(11): 7514-22, 2007 Dec 01.
Article in English | MEDLINE | ID: mdl-18025196

ABSTRACT

The noncanonical NF-kappaB pathway regulates the development and function of multiple organs and cell lineages. We have generated mice harboring a novel mutation in Nfkb2 that prevents the processing of the inhibitory precursor, p100, into the active subunit, p52. Mutant mice express a complex phenotype with abnormalities in a variety of tissues, and with a spectrum that is more severe than in mice carrying a targeted deletion of Nfkb2. Signaling through the noncanonical pathway is ablated due to the absence of p52, resulting in disorganized splenic architecture and disrupted B cell development. The inhibitory precursor form of NF-kappaB2 interacts with RelA, preventing activation of RelA dimers in response to both canonical and noncanonical stimuli, which in combination with p52 deficiency, results in defective lymph node formation and bone homeostasis. These findings demonstrate a key role for NF-kappaB2 in the regulation of RelA activation and suggest overlap in the function of NF-kappaB members in canonical and noncanonical pathway signaling.


Subject(s)
NF-kappa B p52 Subunit/physiology , Animals , B-Lymphocytes/immunology , Female , Male , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mutation , NF-kappa B p52 Subunit/genetics , Osteoclasts/immunology , Pedigree , T-Lymphocytes/immunology , Transcription Factor RelA/physiology
8.
Cell ; 128(6): 1173-86, 2007 Mar 23.
Article in English | MEDLINE | ID: mdl-17382885

ABSTRACT

Platelets are anuclear cytoplasmic fragments essential for blood clotting and wound healing. Despite much speculation, the factors determining their life span in the circulation are unknown. We show here that an intrinsic program for apoptosis controls platelet survival and dictates their life span. Pro-survival Bcl-x(L) constrains the pro-apoptotic activity of Bak to maintain platelet survival, but as Bcl-x(L) degrades, aged platelets are primed for cell death. Genetic ablation or pharmacological inactivation of Bcl-x(L) reduces platelet half-life and causes thrombocytopenia in a dose-dependent manner. Deletion of Bak corrects these defects, and platelets from Bak-deficient mice live longer than normal. Thus, platelets are, by default, genetically programmed to die by apoptosis. The antagonistic balance between Bcl-x(L) and Bak constitutes a molecular clock that determines platelet life span: this represents an important paradigm for cellular homeostasis, and has profound implications for the diagnosis and treatment of disorders that affect platelet number and function.


Subject(s)
Apoptosis , Blood Platelets/cytology , Cell Nucleus/metabolism , bcl-2 Homologous Antagonist-Killer Protein/metabolism , bcl-X Protein/metabolism , Animals , Biomimetics , Biphenyl Compounds/pharmacology , Caspases/metabolism , Crosses, Genetic , Ethylnitrosourea/pharmacology , Female , Male , Mice , Mice, Inbred BALB C , Models, Molecular , Mutagenesis/drug effects , Nitrophenols/pharmacology , Piperazines/pharmacology , Protein Structure, Tertiary , Sulfonamides/pharmacology , Thrombocytopenia/chemically induced , Thrombocytopenia/genetics , Thrombocytopenia/metabolism , bcl-2 Homologous Antagonist-Killer Protein/genetics , bcl-X Protein/antagonists & inhibitors , bcl-X Protein/chemistry , bcl-X Protein/genetics
9.
Proc Natl Acad Sci U S A ; 103(44): 16442-7, 2006 Oct 31.
Article in English | MEDLINE | ID: mdl-17062753

ABSTRACT

An N-ethyl-N-nitrosourea mutagenesis screen in mice was performed to isolate regulators of circulating platelet number. We report here recessive thrombocytopenia and kidney disease in plt1 mice, which is the result of a severe but partial loss-of-function mutation in the gene encoding glycoprotein-N-acetylgalactosamine-3-beta-galactosyltransferase (C1GalT1), an enzyme essential for the synthesis of extended mucin-type O-glycans. Platelet half-life and basic hemostatic parameters were unaffected in plt1/plt1 mice, and the thrombocytopenia and kidney disease were not attenuated on a lymphocyte-deficient rag1-null background. gpIbalpha and podocalyxin were found to be major underglycosylated proteins in plt1/plt1 platelets and the kidney, respectively, implying that these are key targets for C1GalT1, appropriate glycosylation of which is essential for platelet production and kidney function. Compromised C1GalT1 activity has been associated with immune-mediated diseases in humans, most notably Tn syndrome and IgA nephropathy. The disease in plt1/plt1 mice suggests that, in addition to immune-mediated effects, intrinsic C1Gal-T1 deficiency in megakaryocytes and the kidney may contribute to pathology.


Subject(s)
Galactosyltransferases/metabolism , Kidney Diseases/metabolism , Thrombocytopenia/metabolism , Animals , Blood Platelets/metabolism , Blood Platelets/pathology , Cell Line , Cell Proliferation , Female , Galactosyltransferases/genetics , Glycosylation , Humans , Kidney Diseases/genetics , Kidney Diseases/pathology , Male , Mice , Mutation/genetics , Survival Rate , Thrombocytopenia/genetics , Thrombocytopenia/pathology
10.
Proc Natl Acad Sci U S A ; 101(17): 6553-8, 2004 Apr 27.
Article in English | MEDLINE | ID: mdl-15071178

ABSTRACT

Genetic screens in lower organisms, particularly those that identify modifiers of preexisting genetic defects, have been used successfully to order components of complex signaling pathways. To date, similar suppressor screens have not been used in vertebrates. To define the molecular pathways regulating platelet production, we have executed a large-scale modifier screen with genetically thrombocytopenic Mpl(-/-) mice by using N-ethyl-N-nitrosourea mutagenesis. Here we show that mutations in the c-Myb gene cause a myeloproliferative syndrome and supraphysiological expansion of megakaryocyte and platelet production in the absence of thrombopoietin signaling. This screen demonstrates the utility of large-scale N-ethyl-N-nitrosourea mutagenesis suppressor screens in mice for the simultaneous discovery and in vivo validation of targets for therapeutic discovery in diseases for which mouse models are available.


Subject(s)
Blood Platelets/cytology , Genes, Suppressor , Genes, myb , Mutation , Neoplasm Proteins/physiology , Proto-Oncogene Proteins/physiology , Receptors, Cytokine/physiology , Signal Transduction , Thrombopoietin/metabolism , Animals , Cell Lineage , Female , Flow Cytometry , Homozygote , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Neoplasm Proteins/genetics , Phenotype , Proto-Oncogene Proteins/genetics , Receptors, Cytokine/genetics , Receptors, Thrombopoietin
SELECTION OF CITATIONS
SEARCH DETAIL
...